172 related articles for article (PubMed ID: 21055454)
1. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
2. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
4. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
[TBL] [Abstract][Full Text] [Related]
5. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Marra M; Salzano G; Leonetti C; Tassone P; Scarsella M; Zappavigna S; Calimeri T; Franco R; Liguori G; Cigliana G; Ascani R; La Rotonda MI; Abbruzzese A; Tagliaferri P; Caraglia M; De Rosa G
Nanomedicine; 2011 Dec; 7(6):955-64. PubMed ID: 21453789
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Porru M; Zappavigna S; Salzano G; Luce A; Stoppacciaro A; Balestrieri ML; Artuso S; Lusa S; De Rosa G; Leonetti C; Caraglia M
Oncotarget; 2014 Nov; 5(21):10446-59. PubMed ID: 25431953
[TBL] [Abstract][Full Text] [Related]
8. Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].
Gou J; Zhang K; Tang X
Expert Opin Ther Pat; 2012 Nov; 22(11):1367-75. PubMed ID: 22925002
[TBL] [Abstract][Full Text] [Related]
9. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
10. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
Kim TH; Jiang HH; Youn YS; Park CW; Tak KK; Lee S; Kim H; Jon S; Chen X; Lee KC
Int J Pharm; 2011 Jan; 403(1-2):285-91. PubMed ID: 21035530
[TBL] [Abstract][Full Text] [Related]
13. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain.
Parikh T; Bommana MM; Squillante E
Eur J Pharm Biopharm; 2010 Mar; 74(3):442-50. PubMed ID: 19941957
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
[TBL] [Abstract][Full Text] [Related]
18. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain.
Caraglia M; Luongo L; Salzano G; Zappavigna S; Marra M; Guida F; Lusa S; Giordano C; De Novellis V; Rossi F; Abbruzzese Saccardi A; De Rosa G; Maione S
Mol Pharm; 2013 Mar; 10(3):1111-8. PubMed ID: 23327778
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H
Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852
[TBL] [Abstract][Full Text] [Related]
20. Bone substitute materials delivering zoledronic acid: physicochemical characterization, drug load, and release properties.
Sörensen TC; Arnoldi J; Procter P; Robioneck B; Steckel H
J Biomater Appl; 2013 Feb; 27(6):727-38. PubMed ID: 22090432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
